May oxygen-ozone therapy improves cardiovascular disorders

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 2, 2009, Pages 78-85

  Bocci, Velio ^a   Travagli, Valter ^a   Zanardi, Iacopo ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Age related macular degeneration; Chronic heart failure; Chronic limb ischemia; Chronic oxidative stress; Ictus; Ozone therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; CHELATING AGENT; CLOPIDOGREL; CORTICOSTEROID; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; OZONE; PLACEBO; POLYUNSATURATED FATTY ACID; PYRIDOXINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD AUTOTRANSFUSION; BONE NECROSIS; BRAIN ISCHEMIA; BRAIN TUMOR; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; CUSHING SYNDROME; CYTOKINE RELEASE; DERMATITIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLAUCOMA; HEART FAILURE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFLAMMATION; INFLAMMATORY DISEASE; LYMPHOMA; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; OXYGEN THERAPY; OZONE THERAPY; PAIN; PROGNOSIS; RETINA MACULA DEGENERATION; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SICKLE CELL ANEMIA; SOLID TUMOR; STOMACH ULCER; TREATMENT FAILURE; VIRUS INFECTION;

AGED; AGING; BLOOD TRANSFUSION, AUTOLOGOUS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; EXTREMITIES; HUMANS; INFLAMMATION; ISCHEMIA; MACULAR DEGENERATION; OXIDATIVE STRESS; OXYGEN; OXYGEN CONSUMPTION; OZONE;

EID: 68349121762     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909788488681     Document Type: Article

References (112)

1. Laaksonen, D.E.; Niskanen, L.; Lakka, H.M.; Lakka, T.A.; Uusitupa, M. Epidemiology and treatment of the metabolic syndrome. Ann. Med., 2004, 36, 332-346.
2. Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet, 2005, 365, 1415-1428.
3. Bocci V. Ozone. A new medical drug, Springer: Dordrecht, 2005; pp.132-144.
4. Halliwell, B. Antioxidants in human health and disease. Annu. Rev. Nutr., 1996, 16, 33-50.
5. Rhen, T.; Cidlowski, J.A. Antiinflammatory action of glucocorticoids new mechanisms for old drugs. N. Engl. J. Med., 2005, 353, 1711-1723.
6. FitzGerald, G.A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med., 2001, 345, 433-442.
7. Beardsley S. Avoiding another Vioxx. Sci. Am., 2005, 292, 16,18.
8. Farquharson, C.A.; Butler, R.; Hill, A.; Belch, J.J.; Struthers, A.D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation, 2002, 106, 221-226.
9. Lambeth, J.D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol., 2004, 4, 181-189.
10. Schiffrin, E.L. Vascular and cardiac benefits of angiotensin receptor blockers. Am. J. Med., 2002, 113, 409-418.
11. Baykal, Y.; Yilmaz, M.I.; Celik, T.; Gok, F.; Rehber, H.; Akay, C.; Kocar, I.H. Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J. Hypertens., 2003, 21, 1207-1211.
12. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res., 1992, 33, 1569-1582.
13. Spencer, F.A.; Allegrone, J.; Goldberg, R.J.; Gore, J.M.; Fox, K.A.; Granger, C.B.; Mehta, R.H.; Brieger, D. GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann. Intern. Med., 2004, 140, 857-866.
14. Liao, J.K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest., 2002, 110, 285-288.
15. Roberts, W.C. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am. J. Cardiol., 1996, 78, 377-378.
16. Katano, H.; Pesnicak, L.; Cohen, J.I. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc. Natl. Acad. Sci. USA, 2004, 101, 4960-4965.
17. Vollmer, T.; Key, L.; Durkalski, V.; Tyor, W.; Corboy, J.; Markovic-Plese S.; Preiningerova, J.; Rizzo, M; Singh, I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet, 2004, 363, 1607-1608.
18. Lane, R.; Phillips, M. Rhabdomyolysis. BMJ, 2003, 327, 115-116.
19. Morris, C.R.; Kuypers, F.A.; Larkin, S.; Sweeters, N.; Simon, J.; Vichinsky, E.P.; Styles, L.A. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br. J. Haematol., 2000, 111, 498-500.
20. Gonzalez, F.M.; Shiva, S.; Vincent, P.S.; Ringwood, L.A.; Hsu, L.Y.; Hon, Y.Y.; Aletras, A.H.; Cannon, R.O. 3rd; Gladwin, M.T.; Arai, A.E. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation, 2008, 117, 2986-2994.
21. Bocci, V.; Aldinucci, C. Rational bases for using oxygenozonetherapy as a biological response modifier in sickle cell anemia and beta-thalassemia: a therapeutic perspective. J. Biol. Regul. Homeost. Agents, 2004, 18, 38-44.
22. Fontana, L.; McNeill, K.L.; Ritter, J.M.; Chowienczyk, P.J. Effects of vitamin C and of a cell permeable superoxide dismutase mimetic on acute lipoprotein induced endothelial dysfunction in rabbit aortic rings. Br. J. Pharmacol., 1999, 126, 730-734.
23. Kirkham, P.; Rahman; I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol. Ther., 2006, 111, 476-494.
24. Laukkanen, M.O.; Kivelä, A.; Rissanen, T.; Rutanen, J.; Karkkainen, M.K.; Leppanen, O.; Bräsen, J.H.; Yla-Herttuala, S. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation, 2002, 106, 1999-2003.
25. Nemoto, S.; Finkel, T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science, 2002, 295, 2450-2452.
26. Pandolfi, S.; Bonafè, M.; Di Tella, L.; Tiberi, L.; Salvioli, S.; Monti, D.; Sorbi, S.; Franceschi, C. p66(shc) is highly expressed in fibroblasts from centenarians. Mech. Ageing Dev., 2005, 126, 839-844.
27. Das, U.N. Folic acid says NO to vascular diseases. Nutrition, 2003, 19, 686-692.
28. Riksen, N.P.; Rongen, G.A.; Blom, H.J.; Russel, F.G.; Boers, G.H.; Smits, P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc. Res., 2003, 59, 271-276.
29. Blann, A.D.; Landray, M.J.; Lip, G.Y. ABC of antithrombotic therapy: An overview of antithrombotic therapy. BMJ, 2002, 325, 762-765.
30. Belluzzi, A.; Brignola, C.; Campieri, M.; Pera, A.; Boschi, S.; Miglioli, M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med., 1996, 334, 1557-1560.
31. Mori, T.A.; Woodman, R.J.; Burke, V.; Puddey, I.B.; Croft, K.D.; Beilin, L.J. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic. Biol. Med., 2003, 35, 772-781.
32. Knudtson, M.L.; Wyse, D.G.; Galbraith, P.D.; Brant, R.; Hildebrand, K.; Paterson, D.; Richardson, D.; Burkart, C.; Burgess, E. Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) Investigators. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA, 2002, 287, 481-486.
33. Atwood, K.C.; Woeckner, E.; Baratz, R.S.; Sampson, W.I. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned. Medscape J. Med., 2008, 10, 115.
34. Ono, H.; Osanai, T.; Ishizaka, H.; Hanada, H.; Kamada, T.; Onodera, H.; Fujita, N.; Sasaki, S.; Matsunaga, T.; Okumura, K. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am. Heart J., 2004, 148, 611-617.
35. Fontana, L.; Meyer, T.E.; Klein, S.; Holloszy, J.O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl. Acad. Sci. USA, 2004, 101, 6659-6663.
36. Maini, R.N.; Feldmann, M. How does infliximab work in rheumatoid arthritis? Arthritis Res., 2002, 4, S22-S28.
37. Emery, P. Treatment of rheumatoid arthritis. BMJ, 2006, 332, 152-155.
38. Bolton, A.E. Biologic effects and basic science of a novel immune-modulation therapy. Am. J. Cardiol., 2005, 95, 24C-29C.
39. Gullestad, L.; Aukrust, P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am. J. Cardiol., 2005, 95, 17C-23C.
40. Mann, D.L. Targeted anticytokine therapy and the failing heart. Am. J. Cardiol., 2005, 95, 9C-16C.
41. Torre-Amione, G. Immune activation in chronic heart failure. Am. J. Cardiol., 2005, 95, 3C-8C.
42. El-Menyar, A.A. Cytokines and myocardial dysfunction: state of the art. J. Card. Fail, 2008, 14, 61-74.
43. Bulmer, J.; Bolton, A.E.; Pockley, A.G. Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations. J. Biol. Regul. Homeost. Agents., 1997, 11, 104-110.
44. Babaei, S.; Stewart, D.J.; Picard, P.; Monge, J.C. Effects of Vaso- Care therapy on the initiation and progression of atherosclerosis. Atherosclerosis, 2002, 162, 45-53.
45. Torre-Amione, G.; Sestier, F.; Radovancevic, B.; Young, J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J. Am. Coll. Cardiol., 2004, 44, 1181-1186.
46. Torre-Amione, G.; Sestier, F.; Radovancevic, B.; Young, J. Broad modulation of tissue responses (immune activation) by celacade may favorably influence pathologic processes associated with heart failure progression. Am. J. Cardiol., 2005, 95, 30C-37C.
47. Torre-Amione, G.; Anker, S.D.; Bourge, R.C.; Colucci, W.S.; Greenberg, B.H.; Hildebrandt, P.; Keren, A.; Motro, M.; Moyé, L.A.; Otterstad, J.E.; Pratt, C.M.; Ponikowski, P.; Rouleau, J.L.; Sestier, F.; Winkelmann, B.R.; Young, J.B. Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet, 2008, 371, 228-236.
48. Tracey, K.J. The inflammatory reflex. Nature, 2002, 420, 853-859.
49. Pavlov, V.A.; Tracey, K.J. The cholinergic anti-inflammatory pathway. Brain Behav. Immun., 2005, 19, 493-499.
50. O'Neill, W.W.; Martin, J.L.; Dixon, S.R.; Bartorelli, A.L.; Trabattoni, D.; Oemrawsingh, P.V.; Atsma, D.E.; Chang, M.; Marquardt, W.; Oh, J.K.; Krucoff, M.W.; Gibbons, R.J.; Spears, J.R. AMIHOT Investigators. Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J. Am. Coll. Cardiol., 2007, 50, 397-405.
51. Bocci V. Comparative clinical studies between HOT and ozone-therapy in selected chronic pathologies are urgently needed. Arch. Med. Res., 2006, 37, 919.
52. Castanotto, D.; Rossi, J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature, 2009, 457, 426-433.
53. Melton, L. The antioxidant myth. New Sci., 2006, 191, 40-43.
54. Hennekens, C.H.; Buring, J.E.; Peto, R. Antioxidant vitamins-benefits not yet proved. N. Engl. J. Med., 1994, 330, 1080-1081.
55. Packer, L.; Witt, E.H.; Tritschler, H.J. Alpha-lipoic acid as a biological antioxidant. Free Radic. Biol. Med., 1995, 19, 227-250.
56. Omenn, G.S.; Goodman, G.E.; Thornquist, M.D.; Balmes, J.; Cullen, M.R.; Glass, A.; Keogh, J.P.; Meyskens, F.L.; Valanis, B.; Williams, J.H.; Barnhart, S.; Hammar, S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med., 1996, 334, 1150-1155.
57. Clinton, S.K. Lycopene: chemistry, biology, and implications for human health and disease. Nutr. Rev., 1998, 56, 35-51.
58. McCall, M.R.; Frei, B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic. Biol. Med., 1999, 26, 1034-1053.
59. Bender, D.A. Daily doses of multivitamin tablets. BMJ, 2002, 325, 173-174.
60. Vivekananthan, D.P.; Penn, M.S.; Sapp, S.K.; Hsu, A.; Topol, E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet, 2003, 361, 2017-2023.
61. Seifried, H.E.; McDonald, S.S.; Anderson, D.E.; Greenwald, P.; Milner, J.A. The antioxidant conundrum in cancer. Cancer Res., 2003, 63, 4295-4298.
62. Polidori, M.C.; Mecocci, P.; Levine, M.; Frei, B. Short-term and long-term vitamin C supplementation in humans dose-dependently increases the resistance of plasma to ex vivo lipid peroxidation. Arch. Biochem. Biophys., 2004, 423, 109-115.
63. Ames, B.N. A role for supplements in optimizing health: the metabolic tune-up. Arch. Biochem. Biophys., 2004, 423, 227-234.
64. Editorial. Lack of evidence for benefit of multivitamins. Lancet, 2006, 367, 1704.
65. Mudway, I.S.; Behndig, A.F.; Helleday, R.; Pourazar, J.; Frew, A.J.; Kelly, F.J.; Blomberg, A. Vitamin supplementation does not protect against symptoms in ozone-responsive subjects. Free Radic. Biol. Med., 2006, 40, 1702-1712.
66. Harrison, F.E.; May, J.M. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic. Biol. Med., 2009, 46, 719-730.
67. Roberts, L.J. 2nd; Oates, J.A.; Linton, M.F.; Fazio, S.; Meador, B.P.; Gross, M.D.; Shyr, Y.; Morrow, J.D. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic. Biol. Med., 2007, 43, 1388-1393.
68. Peng, J.; Jones, G.L.; Watson, K. Stress proteins as biomarkers of oxidative stress: effects of antioxidant supplements. Free Radic. Biol. Med., 2000, 28, 1598-1606.
69. Bridgeman, M.M.; Marsden, M.; Selby, C.; Morrison, D.; MacNee, W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax, 1994, 49, 670-675.
70. Gillissen, A.; Jaworska, M.; Orth, M.; Coffiner, M.; Maes, P.; App, E.M.; Cantin, A.M.; Schultze-Werninghaus, G. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir. Med., 1997, 91, 159-168.
71. Mendiratta, S.; Qu, Z.C.; May, J.M. Erythrocyte ascorbate recycling: antioxidant effects in blood. Free Radic. Biol. Med., 1998, 24, 789-797.
72. Dickinson, D.A.; Forman, H.J. Cellular glutathione and thiols metabolism. Biochem. Pharmacol., 2002, 64, 1019-1026.
73. Wilson, J.X. The physiological role of dehydroascorbic acid. FEBS Lett., 2002, 527, 5-9.
74. Doroshow, J.H. Glutathione peroxidase and oxidative stress. Toxicol. Lett., 1995, 82/83, 395-398.
75. Tacchini, L.; Pogliaghi, G.; Radice, L.; Bernelli-Zazzeram A.; Cairo, G. Post-transcriptional control of increased hepatic catalase gene expression in response to oxidative stress. Redox Rep., 1996, 2, 273-278.
76. Wang, P.; Chen, H.; Qin, H.; Sankarapandi, S.; Becher, M.W.; Wong, P.C.; Zweier, J.L. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc. Natl. Acad. Sci. USA, 1998, 95, 4556-4560.
77. Chen, Z.; Oberley, T.D.; Ho, Y.; Chua, C.C.; Siu, B.; Hamdy, R.C.; Epstein, C.J.; Chua, B.H. Overexpression of CuZnSOD in coronary vascular cells attenuates myocardial ischemia/reperfusion injury. Free Rad. Biol. Med., 2000, 29, 589-596.
78. Csonka, C.; Pataki, T.; Kovacs, P.; Müller, S.L.; Schroeter, M.L.; Tosaki, A.; Blasig, I.E. Effects of oxidative stress on the expression of antioxidative defense enzymes in spontaneously hypertensive rat hearts. Free Radic. Biol. Med., 2000, 29, 612-619.
79. Bocci, V. Does ozone therapy normalize the cellular redox balance? Med. Hypotheses, 1996, 46, 150-154.
80. León, O.S.; Menéndez, S.; Merino, N.; Castillo, R.; Sam, S.; Pérez, L.; Cruz, E.; Bocci, V. Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediators Inflamm., 1998, 7, 289-294.
81. Larini, A.; Bianchi, L.; Bocci, V. The ozone tolerance: I) Enhancement of antioxidant enzymes is ozone dose-dependent in Jurkat cells. Free Radic. Res., 2003, 37, 1163-1168.
82. Bocci, V. Scientific and medical aspects of ozone therapy. State of the art. Arch. Med. Res., 2006, 37, 425-435.
83. Bocci, V. Is it true that ozone is always toxic? The end of a dogma. Toxicol. Appl. Pharmacol., 2006, 216, 493-504.
84. Bocci, V.A. Why orthodox medicine has not yet taken advantage of ozone therapy. Arch. Med. Res., 2008, 39, 259-260.
85. Bocci, V.; Aldinucci, C.; Mosci, F.; Carraro, F.; Valacchi, G. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm., 2007, 26785.
86. Elbirt, K.K.; Bonkovsky, H.L. Heme oxygenase: recent advances in understanding its regulation and role. Proc. Assoc. Am. Physicians, 1999, 111, 438-447.
87. Snyder, S.H.; Barañano, D.E. Heme oxygenase: a font of multiple messengers. Neuropsychopharmacology, 2001, 25, 294-298.
88. Zuckerbraun, B.S.; Billiar, T.R. Heme oxygenase-1: a cellular Hercules. Hepatology, 2003, 37, 742-744.
89. Abraham, N.G.; Kappas, A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev., 2008, 60, 79-127.
90. Bocci, V. In Oxygen-ozone therapy. A critical evaluation, Bocci, Ed.; Chap. 22, Kluwer Academic Publisher: Dordrecht, 2002; pp. 233-240.
91. Goldman, M. Cancer risk of low-level exposure. Science, 1996, 271, 1821-1822.
92. Calabrese, E.J. Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences. Environ. Pollut., 2005, 138, 379-411.
93. Jacobs, M.T. Untersuchung uber zwishenfalle und typische komplikationen in der ozon-sauerstoff-therapie. OzoNachrichten, 1982, 5, 1-5.
94. Travagli, V.; Zanardi, I.; Silvietti, A.; Bocci, V. A physicochemical investigation on the effects of ozone on blood. Int. J. Biol. Macromol., 2007, 41, 504-511.
95. Bocci, V. The case for oxygen-ozonetherapy. Br. J. Biomed. Sci., 2007, 64, 44-49.
96. Rokitanski, O.; Rokitanski, A.; Steriner, J.; Trubel, W.; Viebahn, R.; Washuttl, J. Die ozontherapie bei peripheren, arteriellen durchblutungs-storungen; klinik, biochemische und blutgasanalytische untersuchungen. Wasser, Ozon-Weltkongress, Berlin 1981. p. 53-75.
97. Matassi, R.; D'Angelo, F.; Bisetti, P.; Colombo, R.; Vaghi, M. Terapia con ozono per via parenterale nelle arteropatie obliteranti periferiche: meccanismo biochimico e risultati clinici. Il Giornale di Chirurgia, 1987, VIII, 109-111.
98. Giunta, R.; Coppola, A.; Luongo, C.; Sammartino, A.; Guastafierro, S.; Grassia, A.; Giunta, L.; Mascolo, L.; Tirelli, A.; Coppola, L. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann. Hematol., 2001, 80, 745-748.
99. Tylicki, L.; Nieweg..owski, T.; Biedunkiewicz, B.; Burakowski, S.; Rutkowski, B. Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs - pilot study. Int. J. Artif. Organs., 2001, 24, 79-82.
100. Tylicki, L.; Nieweglowski, T.; Biedunkiewicz, B.; Chamienia, A.; Debska-Slizien, A.; Aleksandrowicz, E.; Lysiak-Szydlowska, W.; Rutkowski, B. The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. Int. J. Artif. Organs, 2003, 26, 297-303.
101. Clavo, B.; Pérez, J.L.; López, L.; Suárez, G.; Lloret, M.; Rodríguez, V.; Macías, D.; Santana, M.; Morera, J.; Fiuza, D.; Robaina, F.; Günderoth, M. Effect of ozone therapy on muscle oxygenation. J. Altern. Complement. Med., 2003, 9, 251-256.
102. Clavo, B.; Catalá, L.; Pérez, J.L.; Rodríguez, V.; Robaina, F. Ozone therapy on cerebral blood flow: A preliminary report. Evid. Based Complement. Alternat. Med., 2004, 1, 315-319.
103. Tylicki, L.; Biedunkiewicz, B.; Nieweglowski, T.; Chamienia, A.; Slizien, A.D.; Luty, J.; Lysiak-Szydlowska, W.; Rutkowski, B. Ozonated autohemotherapy in patients on maintenance hemodialysis: influence on lipid profile and endothelium. Artif. Organs, 2004, 28, 234-247.
104. Biedunkiewicz, B.; Tylicki, L.; Nieweglowski, T.; Burakowski, S.; Rutkowski, B. Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: an oxygen-controlled study. Int. J. Artif. Organs, 2004, 27, 29-34.
105. De Monte, A.; van der Zee, H.; Bocci, V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J. Altern. Complement. Med., 2005, 11, 363-367.
106. Merin, O.; Attias, E.; Elstein, D.; Schwalb, H.; Bitran, D.; Zimran, A.; Silberman, S. Ozone administration reduces reperfusion injury in an isolated rat heart model. J. Card. Surg., 2007, 22, 339-342.
107. Wasser, G.H. In Ozon-Handbuch. Grundlagen. Prävention. Therapie; Beck, E.G.; Viebahn-Hänsler, R., Eds.; Ecomed: Landsberg, 1995; V-6.3, pp. 1-12.
108. Olin, J.W. A multicenter, randomized, double-blind, placebo-controlled study of immune modulation therapy in patients with symptomatic peripheral arterial disease: the SIMPADICO Trial. American College of Cardiology 55th Annual Scientific Sessions; March 11-14, 2006, Atlanta, GA. Late-Breaking Clinical Trials I.
109. Sliwa, K.; Ansari, A.A. Immunosuppression as therapy for congestive heart failure. Lancet, 2008, 371, 184-186.
110. Fildes, J.E.; Shaw, S.M.; Yonan, N.; Williams, S.G. Non-specific immunomodulation in chronic heart failure. Lancet, 2008, 37, 2083.
111. Bocci, V. Non-specific immunomodulation in chronic heart failure. Lancet, 2008, 37, 2083.
112. Bocci, V. The failure of the ACCLAIM trial is due to an irrational technology. Int. J. Cardiol., 2009, doi:10.1016/ j.ijcard.2008.10.001, in press.